---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Diagnosis"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Diagnosis. Topics: Clinical diagnosis of the primary ocular tumor, Guideline recommendations on ocular imaging and biopsy of the primary tumor, Staging and screening for distant metastases at diagnosis, Molecular prognostic testing of the primary tumor: methods and risk groups, and 10 further topics. 14 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/diagnosis"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Clinical diagnosis of the primary ocular tumor

> “Careful examination by an experienced clinician remains the most important test to diagnose intraocular melanoma. A small uveal melanoma cannot be distinguished from a nevus. Small uveal lesions are observed for growth before making a diagnosis of melanoma.”
> “Ancillary diagnostic testing, including fluorescein angiography and ultrasonography, can be extremely valuable in establishing and confirming the diagnosis.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

> “Diagnosis is accurately established by clinical examination in over 99% cases.”

Source: [Mahendraraj et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5221652/)

<a id="topic-2.2.1.5-2"></a>

### Guideline recommendations on ocular imaging and biopsy of the primary tumor

> “UM diagnosis is based on clinical examination by ophthalmoscopy, fundus photography and conventional ocular ultrasound (US) in patients presenting with blurred vision or other visual symptoms; however, 13%-30% are diagnosed during routine eye examinations.”
> “Biopsy is not mandatory for typical UM diagnosis, which is well characterised by ophthalmoscopy, fundus photography and conventional ocular US [II, D].”
> “A biopsy is recommended if the clinical diagnosis is uncertain and if it has been discussed with the patient due to the potential risks of the procedure and the uncertainty of a conclusive result [II, A].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-3"></a>

### Staging and screening for distant metastases at diagnosis

> “UM should be staged according to the eighth edition of the AJCC Cancer Staging Manual.”
> “Patients should be screened for distant metastases [liver US or MRI with diffusion-weighted sequences, supplemented by positron emission tomography (PET)–computed tomography (CT) or thoraco-abdomino-pelvic CT for extrahepatic extension].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-4"></a>

### Molecular prognostic testing of the primary tumor: methods and risk groups

> “The most commonly used prognostic tests are FISH, multiplex ligation-dependent probe amplification, microsatellite analysis, single-nucleotide polymorphism array, array comparative genomic hybridisation, targeted NGS and a 12-gene PCR assay based on gene expression profiling (GEP).”
> “A low risk of metastasis is associated with tumours that have normal chromosomes 3 and 8; these tumours often display 6p gain.”
> “Late but infrequent metastatic spread is associated with normal chromosome 3, one or more extra copies of (partial) chromosome 8, GEP class 1 status and with PRAME expression.”
> “A high risk of metastasis is associated with loss of one copy of chromosome 3 or isodisomy of this chromosome, polysomy of chromosome 8q, a GEP class 2 profile and inactivating mutations or deletions of the BAP1 gene located on chromosome 3.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-5"></a>

### Gene expression profile class 1 and class 2: prospective multicenter validation

> “The GEP assay successfully classified 446/459 (97.2%) cases. The GEP was class 1 in 276 cases (61.9%) and class 2 in 170 cases (38.1%).”
> “Metastasis was detected in 3 (1.1%) class 1 cases and 44 (25.9%) class 2 cases”
> “Using multivariate Cox modeling, GEP class had a stronger independent association with metastasis than any other prognostic factor (P<0.0001).”

Source: [Onken et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3404209/)

<a id="topic-2.2.1.5-6"></a>

### Recommended molecular work-up of primary and metastatic tumors

> “If sufficient tumour material is available, the molecular work-up of primary UM could include copy number assessment in chromosomes 3, 6 and 8, GEP, mutational status of BAP1, SF3B1, EIF1AX, and immunohistochemistry for BAP1 and PRAME expression [III, B].”
> “Assessment of mutational status of GNAQ, GNA11, SF3B1 and MBD4 may be recommended in the metastatic setting as results may impact treatment decisions [IV, C].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-7"></a>

### Surveillance imaging of the liver after treatment of the primary tumor

> “There is no prospective evidence that imaging surveillance impacts the outcomes of patients with UM.”
> “Liver function tests have a low sensitivity and do not help detect early metastasis.”
> “Hepatic US has a sensitivity of 96% in detecting liver metastasis from UM but the positive predictive value (PPV) is only 45%.”
> “Gadolinium-enhanced liver MRI with diffusion-weighted sequences has demonstrated sensitivity of nearly 100% and specificity of 80%-99%, with a better ability to detect small lesions compared with US.”
> “Genetic and clinical factors should be used to guide surveillance, as there is no standard approach to detecting metastases in patients with UM [III, A].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-8"></a>

### Sensitivity of hepatic ultrasonography and MRI for surveillance

> “Hepatic ultrasonography and magnetic resonance imaging as surveillance methods have a sensitivity of 95-100% and 83-100%, respectively, to detect metastases without radiation hazard according to prevailing evidence, but computed tomography is necessary for staging.”

Source: [Rantala et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34999237/)

<a id="topic-2.2.1.5-9"></a>

### Liver function test screening for metastasis, COMS trials

> “Based on all patients with reported metastasis, the sensitivity, specificity, positive predictive value and negative predictive value associated with at least one abnormal LFT before first diagnosis of metastasis at any site was 14.7%, 92.3%, 45.7% and 71.0%, respectively.”

Source: [Diener-West et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15197206/)

<a id="topic-2.2.1.5-10"></a>

### Detection of metastases by screening ultrasonography and liver function tests

> “Metastases were diagnosed in 74% of patients (95% confidence interval [95% CI], 59-86) at screening and in 26% (95% CI, 14-41) when the patient consulted a physician because of symptoms that developed before the next scheduled visit.”
> “US was diagnostic in 78% (95% CI, 64-89), at least 1 LFT test was abnormal in 70% of patients (95% CI, 54-82), and a chest X-ray was abnormal in 2% of patients (95% CI, 0-12).”

Source: [Eskelin et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10091801/)

<a id="topic-2.2.1.5-11"></a>

### Staging imaging and biopsy confirmation of metastatic disease

> “Staging of metastatic disease is based on total body CT scan and liver MRI; brain imaging is not required in the absence of central nervous system symptoms; the usefulness of fluorodeoxyglucose (FDG)–PET–CT is still debated.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

> “Diagnosis of melanoma metastasis was confirmed by biopsy in 77.8% of the asymptomatic group and in 76.2% of the symptomatic group.”

Source: [Kim et al. (2010)](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/425938)

<a id="topic-2.2.1.5-12"></a>

### HLA-A∗02:01 testing in the metastatic setting

> “HLA-A∗02:01 peripheral blood testing is mandatory in the metastatic setting [I, A] but can also be considered in the localised setting to facilitate access to adjuvant clinical trials [V, B].”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.5-13"></a>

### HLA-A∗02:01 companion diagnostic: specimen and sequencing method

> “The SeCore CDx HLA Sequencing System is intended for the detection of human leukocyte antigen A-locus (HLA-A) alleles using genomic DNA isolated from whole blood samples.”
> “The SeCore CDx HLA Sequencing System is a Sanger sequence-based method for molecular typing of HLA-A Locus alleles. Sequencing-based typing is a high-resolution method for the identification of HLA polymorphisms.”

Source: [FDA SeCore CDx HLA Sequencing System De Novo decision summary (2022)](https://www.fda.gov/media/163612/download)

<a id="topic-2.2.1.5-14"></a>

### Turnaround of HLA-A∗02:01 testing in practice

> “However, faculty agreed that early testing is a low-burden step that can identify patients who would benefit from tebentafusp, as HLA results return in approximately 4 days, which is often faster than tumor biopsy results.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

Additional sources: [National Comprehensive Cancer Network Uveal Melanoma guideline](https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
